摘要
Abstract
Objective: To study the application value of bevacizumab combined with pemetrexed + pluscisplatin first-line chemotherapy in treating lung cancer. Methods: Advanced non small cell lung cancer patients from January 2011 to December 2012 were enrolled and randomly divided into observation group given bevacizumab combined with pemetrexed + pluscisplatin and control group given pemetrexed +pluscisplatin. Then long-term therapeutic effect index, tumor endocrine index and long-term therapeutic effect index were observed. Results:(1)overall remission condition of observation group were better than those of control group(u=6.782, P<0.05), objective response rate(x2=8.382, P<0.05) and disease control rate(x2=5.992, P<0.05) of observation group were higher than those of control group,the difference was statistically significant(P<0.05);(2)after chemotherapy, VEGF-A, VEGF-B and VEGF-C levels of two groups were lower than those before chemotherapy and VEGF-A(t=6.263, P<0.05), VEGF-B(t=6.094, P<0.05) and VEGF-C(t=5.892, P<0.05) levels of observation group were lower than those of control group, the difference was statistically significant(P<0.05);(3)1 year(x2=6.883, P<0.05), 3 year(x2=7.273, P<0.05) and 5 year(x2=6.274, P<0.05) survival rate and progression free survival(t=9.752, P<0.05), overall survival time(t=7.883, P<0.05) of observation group were higher than those of control group, the difference was statistically significant(P<0.05). Conclusion: Bevacizumab combined with pemetrexed+pluscisplatin have positive clinical value for it is helpful to improve the remission, decreased the level of vascular endothelial growth factor, inhibit tumor angiogenesis, prolonged overall survival time.关键词
肺癌/化疗/贝伐单抗/血管内皮生长因子Key words
Lung cancer/Chemotherapy/Bevacizumab/Vascular endothelial growth factor分类
医药卫生
